持有 昭衍新药(603127)的基金 |
报告期:2022-09-30 |
序号 |
基金代码 |
基金简称 |
持仓市值(元) |
持仓数量(股) |
占基金净值比例(%) |
1 | 002708 | 大摩健康产业混合 | 131,405,358.97 | 2,325,347.00 | 5.10 |
2 | 070099 | 嘉实优质企业混合 | 78,612,473.75 | 1,391,125.00 | 4.71 |
3 | 005535 | 泰信竞争优选混合 | 76,096,139.96 | 1,346,596.00 | 6.92 |
4 | 003230 | 创金合信医疗保健股票A | 73,843,086.26 | 1,306,726.00 | 7.44 |
5 | 003231 | 创金合信医疗保健股票C | 73,843,086.26 | 1,306,726.00 | 7.44 |
6 | 290006 | 泰信蓝筹精选混合 | 73,489,107.62 | 1,300,462.00 | 6.90 |
7 | 010275 | 嘉实优质精选混合A | 62,371,725.79 | 1,103,729.00 | 4.69 |
8 | 010276 | 嘉实优质精选混合C | 62,371,725.79 | 1,103,729.00 | 4.69 |
9 | 010585 | 创金合信医药消费股票A | 25,734,201.92 | 455,392.00 | 6.64 |
10 | 010586 | 创金合信医药消费股票C | 25,734,201.92 | 455,392.00 | 6.64 |
11 | 000870 | 嘉实新收益混合 | 18,990,750.60 | 336,060.00 | 4.87 |
12 | 009893 | 大摩优悦安和混合 | 14,339,129.95 | 253,745.00 | 6.56 |
13 | 000523 | 国投瑞银医疗保健混合 | 14,098,114.80 | 249,480.00 | 6.83 |
14 | 161039 | 富国中证1000指数增强(LOF) | 10,505,209.00 | 185,900.00 | 0.31 |
15 | 001050 | 汇添富成长多因子量化策略股票 | 8,877,721.00 | 157,100.00 | 1.09 |
16 | 004191 | 招商沪深300指数C | 4,501,586.60 | 79,660.00 | 0.87 |
17 | 004190 | 招商沪深300指数A | 4,501,586.60 | 79,660.00 | 0.87 |
18 | 005520 | 国投瑞银创新医疗混合 | 2,167,723.60 | 38,360.00 | 5.23 |
19 | 290005 | 泰信优势增长混合 | 2,056,964.00 | 36,400.00 | 6.31 |
20 | 003238 | 新华外延增长主题灵活配置混合 | 1,650,092.00 | 29,200.00 | 3.31 |
21 | 003333 | 泰信智选成长混合 | 1,561,936.40 | 27,640.00 | 0.77 |
22 | 161038 | 富国新兴成长量化精选混合(LOF) | 1,306,511.20 | 23,120.00 | 1.62 |
23 | 006087 | 华泰柏瑞中证500ETF联接C | 31,645.60 | 560.00 | 0.01 |
24 | 001214 | 华泰柏瑞中证500ETF联接A | 31,645.60 | 560.00 | 0.01 |